Fig. 3From: Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approachTime-activity curves (TAC) for the bone marrow self-absorbed dose as determined via the blood method and for both Lu-177-Octreotate (a) and Lu-177-PSMA-617 therapy (b) (according to Eqs. (3.1) and (3.3)); the patient-specific TACs are shown in black, while the median is presented in redBack to article page